Lumateperone · Caplyta
Small molecule
Also known as ITI-007
Evidence outlook
Approved: Major Depressive Disorder, Schizophrenia, Bipolar Depression
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
track record: Reliable signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT02469155 NCT02469155 · Schizophrenia The trial randomized participants to two lumateperone doses, placebo, or risperidone and used quadruple masking, with 696 participants enrolled. Its clinical primary endpoint, change in PANSS total score at week 6, was not met for either lumateperone dose versus placebo (p=0.972 and p=0.789), so the findings provide well-controlled but inconclusive evidence of benefit. Registry: NCT02469155 | 3 | Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score (6 weeks) 2016-08 | Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score (6 weeks): Lumateperone 14 mg (ITI-007 20 mg Tosylate) -15 units on a scale (Standard Error 1.27) | Lumateperone 42 mg (ITI-007 60 mg Tosylate) -14.6 units on a scale (Standard Error 1.23) vs Placebo -15.1 units on a scale (Standard Error 1.21) | Risperidone -20.5 units on a scale (Standard Error 1.33) | Partial signal | link ↗ |
View 3 more trials
NCT02282761 NCT02282761 · Schizophrenia The trial was randomized, quadruple-blind, placebo-controlled, and included 450 participants, with a clinical primary endpoint measuring change in PANSS score. Results were mixed: the 42 mg dose significantly improved PANSS scores versus placebo, but the 28 mg dose did not, so the evidence supports a moderate grade. Registry: NCT02282761 | 3 | Change From Baseline to Day 28 in Positive and Negative Syndrome Scale (PANSS) Total Score (28 days) 2015-07 | Change From Baseline to Day 28 in Positive and Negative Syndrome Scale (PANSS) Total Score (28 days): Lumateperone 28 mg (ITI-007 40 mg Tosylate) -12.9 units on a scale (Standard Error 1.27) | Lumateperone 42 mg (ITI-007 60 mg Tosylate) -14.5 units on a scale (Standard Error 1.25) vs Placebo -10.3 units on a scale (Standard Error 1.32) | Partial signal | link ↗ |
NCT04959032 NCT04959032 · Schizophrenia This was a randomized, quadruple-blind, placebo-controlled trial in 592 patients that measured time to symptom relapse during a double-blind treatment phase of up to 26 weeks, a hard clinical outcome. Lumateperone cut the risk of relapse by 63% compared with placebo (16.4% vs 38.6% relapsed), a highly statistically significant result. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence. Registry: NCT04959032 | 3 | Time to first symptom relapse during the Double-blind Treatment Phase (Number of days from the randomization date to the first relapse date up to 26 weeks.) 2024-07-25 | Study 304 (NCT04959032), time to relapse during double-blind phase: HR 0.37 (95% CI 0.22-0.65), 63% relapse-risk reduction vs placebo (p=0.0002); relapse rate 16.4% (18 relapses) lumateperone vs 38.6% (44 relapses) placebo | Reliable signal | link ↗ |
NCT01499563 NCT01499563 · Schizophrenia The trial was randomized and fully blinded with placebo and risperidone arms, but its primary comparisons of each lumateperone dose against placebo gave different answers: the 42 mg dose reduced PANSS total score more than placebo (p=0.017) while the 84 mg dose did not (p=0.708). With the primary endpoint met for only one of the two tested doses, this is a mixed result. Registry: NCT01499563 | 2 | Change From Baseline to Day 28 in Positive and Negative Syndrome Scale (PANSS) Total Score 2013-08 | Change From Baseline to Day 28 in Positive and Negative Syndrome Scale (PANSS) Total Score (Change from baseline to Day 28): Lumateperone 42 mg (ITI-007 60 mg Tosylate) -13.2 score on a scale (Standard Error 1.7) | Lumateperone 84 mg (ITI-007 120 mg Tosylate) -8.3 score on a scale (Standard Error 1.7) vs Placebo -7.4 score on a scale (Standard Error 1.7) | Risperidone 4 mg -13.4 score on a scale (Standard Error 1.7) | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (21)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (3)
What this study did
What this study did
What this study did
Phase 4 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Appears in other studies (1)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 1 (1)
What this study did
Competitive landscape
Other Serotonin 5-HT2A / dopamine D1-D2 receptor drugs
Deulumateperone. Compare all 2 Serotonin 5-HT2A / dopamine D1-D2 receptor drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
This drug's own stage for Bipolar Depression: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Lumateperone (Caplyta): this drug | Approved | Small molecule | Serotonin 5-HT2A / dopamine D1-D2 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Cariprazine (Vraylar) | Approved | Small molecule | Dopamine D3/D2 receptor (partial agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Lurasidone | Approved | Small molecule | Dopamine D2/D3 receptor + 5-HT7 receptor, Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| D-Cycloserine / Lurasidone (NRX-101) | Phase 3 | Small molecule | NMDA receptor (glycine site) + dopamine/5-HT receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Deulumateperone | Phase 3(overall) | Small molecule | Serotonin 5-HT2A / dopamine D1-D2 receptor | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| ABBV-932 | Phase 1(overall) | Small molecule | Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(16 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Caplyta (Lumateperone) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (2)
2027 (5)
March 2027 (1)
What to watch
April 2027 (1)
What to watch
June 2027 (2)
July 2027 (1)
What to watch
2028 (4)
2029 (1)
September 2029 (1)
What to watch
2030 (2)
2031 (1)
October 2031 (1)
What to watch
2032 (1)
April 2032 (1)
What to watch
Regulatory and conference events
(5)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent